Journal
CANCER RESEARCH
Volume 76, Issue 22, Pages 6483-6494Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-16-0984
Keywords
-
Categories
Funding
- European Community's Seventh Framework Programme (FP7) [304810 - RAIDs]
- Inserm
- Association pour la Recherche sur le Cancer
- Ligue contre le cancer
Ask authors/readers for more resources
The CCL2 chemokine receptor CCR2 drives cancer by mediating the recruitment of monocytes and myeloid-derived suppressor cells to the tumor microenvironment. In this study, we extend the significance of CCR2 in this setting by identifying a new role for it in mediating recruitment of CD4(+) T regulatory cells (Treg). Following tumor initiation, an expanded population of CCR2(+) Tregs required CCR2 expression to traffic between draining lymph nodes (dLN) and the tumor. This Treg subset was enriched in the fraction of tumor antigen-specific cells in the dLN, where they displayed an activated immunosuppressive phenotype. Notably, in mouse models, low-dose cyclophosphamide treatment preferentially depleted CCR2(+) Treg, enhancing priming of tumor-specific CD8(+) T cells. In the MMTV-PyMT transgenic mouse model of breast cancer and in oral squamous cell carcinoma patients, tumor development was associated with decreased blood frequency and inversely increased tumor frequency of CCR2(+) Tregs. Our results define a novel subset of CCR2(+) Treg involved in tumoral immune escape, and they offer evidence that this Treg subset may be preferentially eradicated by low-dose cyclophosphamide treatment. (C) 2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available